Skip to main content

Menu

Select a tool from the sidebar

Create your free account now!

Sign in to customize and use tools on the sidebar.

Sign InCreate free account
Amgen Inc. logo
AMGN
Amgen Inc.
20:00:01
337.6 $
0.0000 (%0.00)
Previous Close: 341.66
Day Low₺334.0501
Day High₺345
Bid
Ask
Overview
Technicals
Financial Statements
Comments
Archive

AMGN: Amgen Inc. Financials

Amgen Inc. Income Statement

Total revenue
Net income
Gross margin TTM
70.8%
Operating margin TTM
29.06%
Net profit margin TTM
20.99%
Return on investment TTM
89.06%
Period end31/12/202531/12/202431/12/202331/12/2022
Total revenue36,741,000,00033,424,000,00028,190,000,00026,323,000,000
Operating income10,676,000,0007,258,000,0007,897,000,0009,566,000,000
Net income7,711,000,0004,090,000,0006,717,000,0006,552,000,000

All line items

Line item31/12/202531/12/202431/12/202331/12/2022
Total revenue36,741,000,00033,424,000,00028,190,000,00026,323,000,000
Cost of revenue10,729,000,00012,858,000,0008,415,000,0006,406,000,000
Gross profit26,012,000,00020,566,000,00019,775,000,00019,917,000,000
Research and development expenses6,974,000,0005,964,000,0004,784,000,0004,434,000,000
General and administrative expenses06,109,000,00004,573,000,000
Selling and marketing expenses0987,000,0000841,000,000
Selling, general and administrative expenses7,050,000,0007,096,000,0006,179,000,0005,414,000,000
Other expenses1,312,000,000248,000,000879,000,000503,000,000
Operating expenses15,336,000,00013,308,000,00011,842,000,00010,351,000,000
Cost and expenses26,065,000,00026,166,000,00020,293,000,00016,757,000,000
Net interest income-2,755,000,000-3,155,000,000-2,875,000,000-1,406,000,000
Interest income0000
Interest expense2,755,000,0003,155,000,0002,875,000,0001,406,000,000
Depreciation and amortization5,167,000,0005,592,000,0004,071,000,0003,417,000,000
EBITDA16,898,000,00013,356,000,00014,801,000,00012,169,000,000
EBIT11,731,000,0007,764,000,00010,730,000,0008,752,000,000
Non-operating income (excl. interest)-1,055,000,000-506,000,000-2,833,000,000814,000,000
Operating income10,676,000,0007,258,000,0007,897,000,0009,566,000,000
Total other income/expenses (net)-1,700,000,000-2,649,000,000-42,000,000-2,220,000,000
Income before tax8,976,000,0004,609,000,0007,855,000,0007,346,000,000
Income tax expense1,265,000,000519,000,0001,138,000,000794,000,000
Net income from continuing operations7,711,000,0004,090,000,0006,717,000,0006,552,000,000
Net income from discontinued operations0000
Other adjustments to net income0000
Net income7,711,000,0004,090,000,0006,717,000,0006,552,000,000
Net income deductions0000
Bottom line net income7,711,000,0004,090,000,0006,717,000,0006,552,000,000
EPS1481312
Diluted EPS1481212
Weighted average shares outstanding538,000,000541,000,000535,000,000538,000,000
Weighted average diluted shares outstanding542,000,000541,000,000538,000,000541,000,000

Amgen Inc. Balance Sheet

Total assets
Total liabilities & equity
Liquidity ratio MRQ
—
Current ratio MRQ
—
Long-term debt / assets MRQ
50,005,000,000%
Total debt / assets MRQ
—
Period end31/12/202531/12/202431/12/202331/12/2022
Total assets90,586,000,00091,839,000,00097,154,000,00065,121,000,000
Total liabilities81,928,000,00085,962,000,00090,922,000,00061,460,000,000
Total equity8,658,000,0005,877,000,0006,232,000,0003,661,000,000

All line items

Line item31/12/202531/12/202431/12/202331/12/2022
Cash and cash equivalents9,129,000,00011,973,000,00010,944,000,0007,629,000,000
Short-term investments0001,676,000,000
Cash and short-term investments9,129,000,00011,973,000,00010,944,000,0009,305,000,000
Net receivables9,570,000,0007,501,000,0007,942,000,0006,392,000,000
Accounts receivable9,570,000,0006,782,000,0007,268,000,0005,563,000,000
Other receivables0719,000,000674,000,000829,000,000
Inventory6,225,000,0006,998,000,0009,518,000,0004,930,000,000
Prepaid expenses02,139,000,0001,647,000,0001,204,000,000
Other current assets4,133,000,000419,000,000281,000,000355,000,000
Total current assets29,057,000,00029,030,000,00030,332,000,00022,186,000,000
Property, plant and equipment (net)8,515,000,0006,543,000,0005,941,000,0005,427,000,000
Goodwill18,680,000,00018,637,000,00018,629,000,00015,529,000,000
Intangible assets22,276,000,00027,699,000,00032,641,000,00016,080,000,000
Goodwill and intangible assets40,956,000,00046,336,000,00051,270,000,00031,609,000,000
Long-term investments6,804,000,0005,355,000,0004,711,000,0000
Tax assets0000
Other non-current assets5,254,000,0004,575,000,0004,900,000,0005,899,000,000
Total non-current assets61,529,000,00062,809,000,00066,822,000,00042,935,000,000
Other assets0000
Total assets90,586,000,00091,839,000,00097,154,000,00065,121,000,000
Total payables4,104,000,0005,769,000,0004,459,000,0003,904,000,000
Accounts payable2,367,000,0001,908,000,0001,590,000,0001,572,000,000
Other payables1,737,000,0003,861,000,0002,869,000,0002,332,000,000
Accrued expenses15,349,000,00012,451,000,00011,109,000,0009,093,000,000
Short-term debt4,599,000,0003,550,000,0001,443,000,0001,591,000,000
Capital lease obligations (current)0000
Tax payables001,664,000,0001,195,000,000
Deferred revenue0000
Other current liabilities1,437,000,0001,329,000,0001,381,000,0001,099,000,000
Total current liabilities25,489,000,00023,099,000,00018,392,000,00015,687,000,000
Long-term debt50,005,000,00056,549,000,00063,170,000,00037,354,000,000
Capital lease obligations (non-current)0000
Deferred revenue (non-current)0000
Deferred tax liabilities (non-current)1,366,000,0001,616,000,0002,354,000,00011,000,000
Other non-current liabilities5,068,000,0004,698,000,0007,006,000,0008,408,000,000
Total non-current liabilities56,439,000,00062,863,000,00072,530,000,00045,773,000,000
Other liabilities0000
Capital lease obligations0000
Total liabilities81,928,000,00085,962,000,00090,922,000,00061,460,000,000
Treasury stock0000
Preferred stock0000
Common stock34,023,000,00033,533,000,00033,070,000,00032,514,000,000
Retained earnings-25,107,000,000-27,590,000,000-26,549,000,000-28,622,000,000
Additional paid-in capital0000
Accumulated other comprehensive income/loss-258,000,000-66,000,000-289,000,000-231,000,000
Other stockholders' equity0000
Total stockholders' equity8,658,000,0005,877,000,0006,232,000,0003,661,000,000
Total equity8,658,000,0005,877,000,0006,232,000,0003,661,000,000
Minority interest0000
Total liabilities and total equity90,586,000,00091,839,000,00097,154,000,00065,121,000,000
Total investments6,804,000,0005,355,000,0004,711,000,0001,676,000,000
Total debt54,604,000,00060,099,000,00064,613,000,00038,945,000,000
Net debt45,475,000,00048,126,000,00053,669,000,00031,316,000,000

Amgen Inc. Cash Flow Statement

Cash from operations
Cash from investing
Cash flow / share TTM
—
Revenue / share TTM
—
Operating cash flow TTM
—
Period end31/12/202531/12/202431/12/202331/12/2022
Cash from operations9,958,000,00011,490,000,0008,471,000,0009,721,000,000
Cash from investing-1,943,000,000-1,046,000,000-26,204,000,000-6,044,000,000
Cash from financing-10,859,000,000-9,415,000,00021,048,000,000-4,037,000,000
Net change in cash-2,844,000,0001,029,000,0003,315,000,000-360,000,000

All line items

Line item31/12/202531/12/202431/12/202331/12/2022
Net income7,711,000,0004,090,000,0006,717,000,0006,552,000,000
Depreciation and amortization5,167,000,0005,592,000,0004,071,000,0003,417,000,000
Deferred income tax-721,000,000-1,228,000,000-1,273,000,000-1,198,000,000
Stock-based compensation0530,000,000431,000,000401,000,000
Change in working capital-1,978,000,0002,365,000,000-484,000,000-733,000,000
Accounts receivable-2,676,000,000441,000,000-1,015,000,000-746,000,000
Inventory886,000,0002,532,000,000491,000,000-742,000,000
Accounts payable428,000,000312,000,000-402,000,000154,000,000
Other working capital-616,000,000-920,000,000442,000,000601,000,000
Other non-cash items-221,000,000141,000,000-991,000,0001,282,000,000
Net cash from operating activities9,958,000,00011,490,000,0008,471,000,0009,721,000,000
Investments in property, plant and equipment-1,858,000,000-1,096,000,000-1,112,000,000-936,000,000
Acquisitions (net)-53,000,0000-26,989,000,000-3,727,000,000
Purchases of investments00-1,000,000-2,587,000,000
Sales/maturities of investments001,673,000,0001,218,000,000
Other investing activities-32,000,00050,000,000225,000,000-12,000,000
Net cash from investing activities-1,943,000,000-1,046,000,000-26,204,000,000-6,044,000,000
Net debt issuance-5,683,000,000-4,259,000,00025,676,000,0006,622,000,000
Long-term net debt issuance-5,683,000,000-4,259,000,00025,676,000,0006,622,000,000
Short-term net debt issuance0000
Net stock issuance0-200,000,0000-6,360,000,000
Net common stock issuance0-200,000,0000-6,360,000,000
Common stock issuance0000
Common stock repurchased0-200,000,0000-6,360,000,000
Net preferred stock issuance0000
Net dividends paid-5,124,000,000-4,832,000,000-4,556,000,000-4,196,000,000
Common dividends paid-5,124,000,000-4,832,000,000-4,556,000,000-4,196,000,000
Preferred dividends paid0000
Other financing activities-52,000,000-124,000,000-72,000,000-103,000,000
Net cash from financing activities-10,859,000,000-9,415,000,00021,048,000,000-4,037,000,000
Effect of FX changes on cash0000
Net change in cash-2,844,000,0001,029,000,0003,315,000,000-360,000,000
Cash at end of period9,129,000,00011,973,000,00010,944,000,0007,629,000,000
Cash at beginning of period11,973,000,00010,944,000,0007,629,000,0007,989,000,000
Operating cash flow9,958,000,00011,490,000,0008,471,000,0009,721,000,000
Capital expenditure-1,858,000,000-1,096,000,000-1,112,000,000-936,000,000
Free cash flow8,100,000,00010,394,000,0007,359,000,0008,785,000,000
Income taxes paid0000
Interest paid0000